INTRODUCTION: The population of patients with hepatitis C is aging. In some countries, the prevalence of hepatitis C virus (HCV) is actually greater in older patients than in younger individuals. It is also anticipated that hepatitis C will increasingly become a disease of older persons. However, patients older than 70 years are typically excluded from clinical trials. The decision to treat older patients is complex and cannot be made at the sole discretion of the physician. AREAS COVERED: There is an urgent need to analyze treatment outcomes in the elderly to examine response rates in order to aid in therapeutic decision making. EXPERT OPINION: In geriatric HCV-infected patients, dual therapy with pegylated IFN plus ribavirin is associated with a lower sustained virologic response and a higher discontinuation rate. Even the first-generation protease inhibitors are associated with high rates of side effects, in particular in elderly patients with a high prevalence of comorbidities. The recent development of interferon-sparing regimens could change the treatment paradigm in this setting, and a much larger number of patients could have access to the antiviral therapy programs.

Treating hepatitis C in the elderly: the future is near? / Conti, Fabio; Vitale, Giovanni; Andreone, Pietro. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1465-6566. - 15:14(2014), pp. 2019-2028. [10.1517/14656566.2014.945422]

Treating hepatitis C in the elderly: the future is near?

Pietro Andreone
2014

Abstract

INTRODUCTION: The population of patients with hepatitis C is aging. In some countries, the prevalence of hepatitis C virus (HCV) is actually greater in older patients than in younger individuals. It is also anticipated that hepatitis C will increasingly become a disease of older persons. However, patients older than 70 years are typically excluded from clinical trials. The decision to treat older patients is complex and cannot be made at the sole discretion of the physician. AREAS COVERED: There is an urgent need to analyze treatment outcomes in the elderly to examine response rates in order to aid in therapeutic decision making. EXPERT OPINION: In geriatric HCV-infected patients, dual therapy with pegylated IFN plus ribavirin is associated with a lower sustained virologic response and a higher discontinuation rate. Even the first-generation protease inhibitors are associated with high rates of side effects, in particular in elderly patients with a high prevalence of comorbidities. The recent development of interferon-sparing regimens could change the treatment paradigm in this setting, and a much larger number of patients could have access to the antiviral therapy programs.
2014
15
14
2019
2028
Treating hepatitis C in the elderly: the future is near? / Conti, Fabio; Vitale, Giovanni; Andreone, Pietro. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1465-6566. - 15:14(2014), pp. 2019-2028. [10.1517/14656566.2014.945422]
Conti, Fabio; Vitale, Giovanni; Andreone, Pietro
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1237286
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact